BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.

  title={BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.},
  author={M Concepci{\'o}n Dom{\'i}nguez Garrido and Carlota Gutierrez and Erica Riveiro-Falkenbach and Pablo Luis Ortiz and Jos{\'e} Luis Rodr{\'i}guez-Peralto},
  journal={The American Journal of dermatopathology},
  volume={37 10},
Recent advances in targeting BRAF mutations, which occur in roughly 50% of the melanomas, have improved response rates and overall survival in patients with advanced disease. With the increasingly extensive use of the drug, new, nonpreventable, cutaneous and noncutaneous toxicities keep arising as infrequent adverse effects. We report a 55-year-old man with a history of metastatic melanoma treated with the dabrafenib who presented, 10 months after the initiation of the treatment, with… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 13 references

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 2 Excerpts

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

The New England journal of medicine • 2012
View 3 Excerpts

Malignant melanoma and granulomatosis.

The British journal of dermatology • 1997
View 1 Excerpt

Similar Papers

Loading similar papers…